In a study published in Neurology, a group from Alnylam Pharmaceuticals used large-scale protein screening assays to simultaneously analyse many proteins in vast numbers of patient serum samples. This cutting-edge approach allowed them to discover a novel biomarker of hereditary transthyretin-mediated (ATTRv) amyloidosis disease onset and progression. ATTRv amyloidosis, caused by mutation of the transthyretin […]

- Home
- News
- DDW Exclusive Content
- Opinion
- Business
- Regulatory
- Intelligence
Categories
Latest Industry Intelligence
- Cancer Research
- Webinars
- Podcasts
- Archive
- Videos